Home > BI 730357

molecules of the month

<< Back to January

BI 730357

Recent Publication

Oral RORy nuclear receptor antagonist

on-going Ph. II for psoriasis (QD dosing)

50k cmpd high-conc. frag. screen + scaff. hop

ACS Med. Chem. Lett., Jan. 5, 2021

Boehringer Ingelheim, Ridgefield, CT

The Boehringer RORγ antagonist, BI 730357, is an oral once-daily clinical candidate from a new compound class in development for plaque psoriasis. We highlighted two other RORγ modulators last…

this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.

LEARN MORE

BI 730357

this content is exclusive to Premium members

this content is exclusive to
Premium members